Literature DB >> 15068902

Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia.

Yasunori Nakagawa1, Shuichi Yamaguchi, Maki Hasegawa, Tetsuo Nemoto, Miori Inoue, Kenshi Suzuki, Katsuiku Hirokawa, Masanobu Kitagawa.   

Abstract

Survivin, a member of the inhibitor of apoptosis protein (IAP) gene family, has been detected widely in fetal tissue and in a variety of human malignancies. In the current study, we investigated the expression of IAP family proteins in bone marrow samples from acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL) and control cases by quantitative real-time RT-PCR method and an immunohistochemical approach. Overexpression of survivin and cIAP2 mRNA was significant in CLL bone marrow cells (P < 0.05, respectively) compared with control samples. By immunohistochemistry, survivin was detected in a few scattered myeloid cells in all cases of control bone marrow. Concerning the ALL bone marrow, more than half the cases demonstrated positive expression of survivin (8 out of 13), while the majority of CLL cases (20 out of 21) exhibited intense expression of survivin. The differential subcellular localization of survivin was distinct between ALL and CLL cases. ALL cells essentially revealed nuclear localization of survivin as well as cytoplasmic signals in some cases, while CLL cells from the majority of cases predominantly showed cytoplasmic expression. Next, RT-PCR was performed for the expression of survivin and its splicing variant, survivin-2B and survivin-deltaEx3 in ALL and CLL cells, as the distribution of these variants would be regulated by nuclear/cytoplasmic transport system. In both ALL and CLL bone marrow samples, the expression of wild-type survivin was more predominant than that of survivin-2B or survivin-deltaEx3, although the expression of survivin-deltaEx3 was prominent in samples from survivin-expressing ALL cases. Thus, the splicing of survivin mRNA may be differently regulated in ALL and CLL cells, causing distinct manners of nuclear/cytoplasmic transport of survivin protein. In conclusion, our observations indicate a differential regulatory mechanism for the expression of IAP family proteins in ALL and CLL cells, although the functions of IAP families and the mechanisms of nuclear/cytoplasmic transport of survivin should be clarified in future studies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15068902     DOI: 10.1016/j.leukres.2003.10.013

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  13 in total

1.  Immunoexpression of Survivin in non-neoplastic lymphoid tissues and malignant lymphomas using a new monoclonal antibody reactive on paraffin sections.

Authors:  José Vassallo; Talal Al Saati; Randy D Gascoyne; Kathyrn Welsh; John C Reed; Pierre Brousset; Georges Delsol
Journal:  J Hematop       Date:  2010-01-30       Impact factor: 0.196

Review 2.  Nuclear or cytoplasmic expression of survivin: what is the significance?

Authors:  Fengzhi Li; Jie Yang; Nithya Ramnath; Milind M Javle; Dongfeng Tan
Journal:  Int J Cancer       Date:  2005-04-20       Impact factor: 7.396

3.  Cytoplasmic localization of wild-type survivin is associated with constitutive activation of the PI3K/Akt signaling pathway and represents a favorable prognostic factor in patients with acute myeloid leukemia.

Authors:  Juana Serrano-López; Josefina Serrano; Vianihuini Figueroa; Antonio Torres-Gomez; Salvador Tabares; Javier Casaño; Noemi Fernandez-Escalada; Joaquín Sánchez-Garcia
Journal:  Haematologica       Date:  2013-06-28       Impact factor: 9.941

4.  Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias.

Authors:  R Tibes; K T McDonagh; L Lekakis; J M Bogenberger; S Kim; N Frazer; S Mohrland; D Bassett; R Garcia; K Schroeder; V Shanmugam; J Carpten; R T Hagelstrom; C Beaudry; D Von Hoff; T C Shea
Journal:  Invest New Drugs       Date:  2014-12-19       Impact factor: 3.850

5.  Expression of survivin and its four splice variants in colorectal cancer and its clinical significances.

Authors:  Quan-Xing Ge; Yu-Yuan Li; Yu-Qiang Nie; Wen-Ge Zuo; Yan-Lei Du
Journal:  Med Oncol       Date:  2013-03-15       Impact factor: 3.064

6.  Clinical relevance of survivin as a biomarker in neoplasms, especially in adult T-cell leukemias and acute leukemias.

Authors:  Kazuyuki Sugahara; Akiko Uemura; Hitomi Harasawa; Hiroshi Nagai; Yoichi Hirakata; Masao Tomonaga; Kenn Murata; Hiroshi Sohda; Toru Nakagoe; Sin-ichi Shibasaki; Yasuaki Yamada; Shimeru Kamihira
Journal:  Int J Hematol       Date:  2004-07       Impact factor: 2.490

7.  Anti-leukemic response of a NSAID, tolfenamic acid.

Authors:  Robert M Sutphin; Sarah F Connelly; Chris M Lee; Umesh T Sankpal; Don Eslin; Moeez Khan; Hima Pius; Riyaz Basha
Journal:  Target Oncol       Date:  2013-04-23       Impact factor: 4.493

8.  Expression of the survivin-2B splice variant related to the progression of colorectal carcinoma.

Authors:  Gyu-Seok Cho; Tae Sung Ahn; Dongjun Jeong; Jae-Jun Kim; Chang-Jin Kim; Hyun-Deuk Cho; Dong-Kook Park; Moo-Jun Baek
Journal:  J Korean Surg Soc       Date:  2011-06-09

9.  Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein.

Authors:  N Purroy; P Abrisqueta; J Carabia; C Carpio; E Calpe; C Palacio; J Castellví; M Crespo; F Bosch
Journal:  Leukemia       Date:  2014-03-12       Impact factor: 12.883

10.  Overexpression of X-linked inhibitor of apoptosis protein (XIAP) is an independent unfavorable prognostic factor in childhood de novo acute myeloid leukemia.

Authors:  Ki Woong Sung; Jaewon Choi; Yu Kyeong Hwang; Sang Jin Lee; Hee-Jin Kim; Ju Youn Kim; Eun Joo Cho; Keon Hee Yoo; Hong Hoe Koo
Journal:  J Korean Med Sci       Date:  2009-07-29       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.